Interaction between cyclooxygenase-2 and insulin-like growth factor in breast cancer: A new field for prevention and treatment

Oncology Letters

Volumn 3, Issue 3, 2012, Pages 682-688

  Taromaru, Giuliana Cássia Morrone ^a   de Oliveira, Vilmar Marques ^a   Silva, Maria Antonieta Longo Galvão ^a   Montor, Wagner Ricardo ^a   Bagnoli, Fabio ^a   Rinaldi, José Francisco ^a   Aoki, Tsutomu ^a  

^a IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE SÃO PAULO   (Brazil)

Author keywords

Cyclooxygenase 2; Ductal carcinoma in situ; Invasive ductal carcinomas; Tissue microarrays; Type I insulin like growth factor receptor

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; KI 67 ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; SOMATOMEDIN C RECEPTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER PREVENTION; CELL PROLIFERATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFILTRATING DUCTAL CARCINOMA; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

EID: 84855656266     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.532     Document Type: Article

References (51)

1. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M and Cronin WM: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388, 1998.
2. Powles T, Eeles R, Ashley SE, Easton D, Chang J and Dowsett L: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 352: 98-101, 1998.
3. Veronesi U, Maisonneuve P, Sacchini V, Rotmensz N and Boyle P: Tamoxifen for breast cancer among women hysterectomised. Lancet 359: 1122-1124, 2002.
4. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS and Baum M: Arimidex, tamoxifen, alone or in combination (ATAC) trialists' group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9: 45-53, 2008.
5. Li Y and Brown PH: Prevention of ER-negative breast cancer. Recent Results Cancer Res 181: 121-134, 2009.
6. Fosslien E: Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 30: 3-21, 2000.
7. Dempke W, Rie C, Grothey A and Schmoll H: Cyclooxygenase-2: a novel target for cancer chemotherapy. J Cancer Res Clin Oncol 127: 411-417, 2001.
8. Krcova Z, Ehrmann J, Krejci V, Eliopoulos A and Kolar Z: TPL-2/COT and COX-2 in breast cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 152: 21-25, 2008.
9. Martínez-Arribas F, Martín-Garabato E, Zapardiel I, Sánchez J, Lucas AR, Tejerina A and Schneider J: Bax expression in untreated breast cancer: an immunocytometric study of 255 cases. Anticancer Res 28: 2595-2598, 2008.
10. Singh B, Cook KR, Vincent L, Hall CS, Berry JA, Multani AS and Lucci A: Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells. J Surg Res 147: 240-246, 2008.
11. Zhu XG, Tao L, Mei ZR, Wu HP and Jiang ZW: Aspisol inhibits tumor growth and induces apoptosis in breast cancer. Exp Oncol 30: 289-294, 2008.
12. Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H and Isola J: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62: 632-635, 2002.
13. Boland GP, Butt IS, Prasad R, Knox WF and Bundred NJ: COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 90: 423-429, 2004.
14. Sheen-Chen SM, Chou FF, Hsu W, Huang CC, Eng HL and Tang RP: Lack of prognostic value of insulin-like growth factor-1 in patients with breast cancer: analysis with tissue microarray. Anticancer Res 27: 3541-3544, 2007.
15. Werner H and Bruchim I: The insulin-like growth factor-1 receptor on the oncogene. Arch Physiol Biochem 115: 58-71, 2009.
16. Levitt RJ, Buckley J, Blouin MJ, Schaub B, Triche TJ and Pollak M: Growth inhibition of breast epithelial cells by celecoxib is associated with up-regulation of insulin-like growth factor binding protein-3 expression. Biochem Biophys Res Commun 316: 421-428, 2004.
17. Põld M, Krysan K, Põld A, Dohadwala M, Heuze-Vourc'h N, Mao JT, Riedl KL, Sharma S and Dubinett SM: Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer. Cancer Res 64: 6549-6555, 2004.
18. Dabbs DJ: Ductal carcinoma of the breast: nuclear grade as a predictor of S-phase fraction. Human Pathol 24: 652-656, 1993.
19. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991.
20. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al; American Society of Clinical Oncology; College of American Pathologists: American Society of Clinical Oncology/ College of American Pathologists guideline for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145, 2006.
21. Shim JY, Jung An H, Lee YH, Kim SK, Lee KP and Lee KS: Over-expression of Cyclooxygenase-2 is associated with breast carcinoma and its poor prognostic factors. Mod Pathol 16: 1199-1204, 2003.
22. Oliveira VM, Piato S and Silva MA: Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium. Breast Cancer Res Treat 95: 235-241, 2006.
23. Bernard R (ed): Fundamentals of Biostatistics. 2nd edition. Buxbury Press, Boston, MA, 1986.
24. Hwang D, Scollard D, Byrne J and Levine E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90: 455-460, 1998.
25. Buskens CJ, Sivula A, van Rees BP, Haglund C, Offerhaus GJ, van Lanschot JJ and Ristimäki A: Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal esophagus. Gut 52: 1678-1683, 2003.
26. Singh-Ranger G, Salhab M and Mokbel K: The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res Treat 109: 189-198, 2008.
27. Davies G, Salter J, Hills F, Martin L, Sacks N and Dowset M: Correlation of cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res 9: 2652-2656, 2003.
28. Half E, Tang XT, Gwyn K, Sahin A, Wathen K and Sinicrope FA: Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62: 1676-1681, 2002.
29. Tan KB, Yong WP and Putti TC: Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast. Histopathology 44: 24-28, 2004.
30. Perrone G, Santini D, Vincenzi B, Zagami M, La Cesa A, Bianchi A, Altomare V, Primavera A, Battista C, Vetrani A, Tonini G and Rabitti C: COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. Histopathology 46: 561-568, 2005.
31. Howe LR, Subbaramaiah K, Brown AM and Dannenberg AJ: Cyclooxygenase-2: a target for prevention and treatment of breast cancer. Endocr Relat Cancer 8: 97-114, 2001.
32. Benoit V, Relic B, Leval X, Chariot A, Merville MP and Bours V: Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2. Oncogene 23: 1631-1635, 2004.
33. Wang L, Liu LH, Shan BE, Zhang C, Sang MS and Li J: Celecoxib promotes apoptosis of breast cancer cell line MDA-MB-231 through down-regulation of the NK-κB pathway. Chin J Cancer 28: 569-574, 2009.
34. Li RX, Shi F, Wu YY, Wu Y, Guo JJ and Dong DF: The relationship between lymphatic metastasis and serum vascular endothelial growth factor C and cyclooxygenase 2 expression in breast cancer. Zhonghua Yi Xue Za Zhi 88: 88-91, 2008.
35. Yang L, Zhu X and Ran L: Correlations of HER-2, PCNA, Bcl-2, and Bax expression to prognosis of breast cancer. Ai Zheng 26: 756-761, 2007 (In Chinese).
36. Mintz PJ, Habib NA, Jones LJ, Giamas G, Lewis JS, Bowen RL, Coombes RC and Stebbing J: The phosphorylated membrane estrogen receptor and cytoplasmic signaling and apoptosis proteins in human breast cancer. Cancer 113: 1489-1495, 2008.
37. Martínez-Arribas F, Nuñez-Villar MJ, Lucas AR, Sanchez J, Tejerina A and Schneider J: Immunofluorometric study of Bcl-2 and BAX expression in clinical fresh tumor samples from breast cancer patients. Anticancer Res 23: 565-568, 2003.
38. Arun B, Kilic G, Yen C, et al Loss of FHIT expression in breast cancer is correlated with poor prognostic markers: Cancer Epidemiol Biomarkers Prev 14: 1681-1685, 2005.
39. Michael MS, Badr MZ and Badawi AF: Inhibition of cyclooxygenase-2 and activation of peroxisome proliferator-activated receptor-γ synergistically induces apoptosis and inhibits growth of human breast cancer cells. Int J Mol Med 11: 733-736, 2003.
40. Hoque A, Menter DG, Sahin AA, Sneige N and Lippman SM: No increased Ki67 expression in ductal carcinoma in situ associated with invasive breast cancer. Cancer Epidemiol Biomarkers Prev 10: 153-154, 2001.
41. Mylonas I, Makovitzky J, Jeschke U, Briese U, Friese K and Gerber B: Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone. Anticancer Res 25: 1719-1723, 2005.
42. Faratian D, Munro A, Twelves C and Bartlett JM: Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma. Histopathology 54: 254-257, 2009.
43. Shimizu C, Hasegawa T, Tani Y, Takahashi F, Takeuchi M, Watanabe T, Ando M, Katsumata N and Fujiwara Y: Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum Pathol 35: 1537-1542, 2004.
44. Zhang H, Sachdev D, Wang C, Hubel A, Gaillard-Kelly M and Yee D: Detection and downregulation of type I IGF receptor expression by antibody-conjudated quantum dots in breast cancer cells. Breast Cancer Res Treat 114: 277-285, 2009.
45. Ellis MJ, Jenkins S, Hanfelt J, Redington ME, Taylor M, Leek R, Siddle K and Harris A: Insulin-like growth factors in human breast cancer. Breast Cancer Res Treat 52: 175-184, 1998.
46. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, et al: Phosphorylated insulin-like growth factor-1/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68: 10238-103246, 2008.
47. Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Moller S, Ejlertsen B and Mouridsen HT: Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays. J Clin Pathol 60: 397-404, 2007.
48. Levitt R and Pollak M: Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells. Cancer Res 62: 7372-7376, 2002.
49. Jin Q and Esteva FJ: Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 13: 485-498, 2008.
50. Zakikhani M, Blouin MJ, Piura E and Pollak MN: Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 123: 271-279, 2010.
51. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN and Gonzalez-Angulo AM: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27: 3297-3302, 2009.